Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AKRO vs LLY: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

LLY Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 7–3 Matrix Metrics)

LLY Overall Winner 6-Pillar Tally: AKRO 0 – 6 LLY Matrix Metrics: AKRO 3 – 7 LLY

As of Nov 20, 2026, Eli Lilly & Co. (LLY) is the stronger overall head-to-head candidate over Akero Therapeutics, Inc. (AKRO) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AKRO carries a Unified Composite Score of 60.0/100 (BUY) at $54.65 (N/M Forward P/E, 0.0% operating margin), whereas LLY carries 41.4/100 (SELL) at $1,347.11 (26.5x Forward P/E, 51.2% operating margin).

  • Composite vs. Pillar Nuance: While AKRO currently prints a higher short-term Unified Composite Score (60.0/100 BUY vs. LLY 41.4/100 SELL), LLY captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (51.2% vs. 0.0% operating margin) and revenue trajectory (+38.6% vs. +0.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AKRO vs LLY
AKRO NASDAQ
Akero Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$54.65
+0.32% 1D
Market Cap $4.5B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.90β · 2% Vol
Unified Composite Score
60.0 / 100 BUY
Tech 55.0 Fund 52.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.8% over 20 days), RSI 67
RSI-14: 67.3 · SMA20: $54.36 · SMA50: $52.91
LLY NYSE Head-to-Head Winner
Eli Lilly & Co.
Pharmaceutical Preparations
$1,347.11
-0.3% 1D
Market Cap $1.20T
TTM Revenue $86.5B
Forward P/E 26.5x
Beta / 30D Vol 0.32β · 36% Vol
Unified Composite Score
41.4 / 100 SELL
Tech 39.0 Fund 44.0 Flow 67.0 Mom 21.1
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 49
RSI-14: 49.5 · SMA20: $1,383.91 · SMA50: $1,266.92

6-Pillar Scorecard Institutional Category Breakdown (AKRO 0 – 6 LLY)

Columns: Metric · AKRO · LLY
1. Valuation Multiples LLY
Forward P/E N/M 26.5x
Trailing P/E N/M 44.9x
PEG Ratio N/M 1.28x
EV / Revenue N/M 14.4x
2. Growth & Scale LLY
Revenue Growth (YoY) +0.0% +38.6%
Earnings Growth (YoY) +0.0% +16.3%
TTM Revenue (USD) N/A $86.5B
Market Cap $4.5B $1.20T
3. Profitability & Quality LLY
Gross Margin N/A 83.6%
Operating Margin 0.0% 51.2%
Net Profit Margin 0.0% 31.9%
Return on Equity (ROE) -34.5% 86.0%
4. Balance Sheet & Cash Flow LLY
Cash Generation (TTM) N/A $11.7B
Cash Flow Margin N/A 13.5%
Net Cash / Leverage $11.95 Book/Sh · -34.5% ROE $44.6B Net Debt (1.23x D/E)
Dividend Yield None (0.00%) 0.48%
5. Options & Positioning LLY
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 7.3% (30th %ile) 34.2% (23rd %ile)
Put/Call OI Skew N/A 0.95x (Balanced)
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat LLY
OpEx & R&D Intensity N/A 32.4% of Rev ($28.0B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Pharmaceutical Preparations Operator Incretin Metabolic, Obesity & Cardiometabolic Biopharma Leader

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AKRO (3) vs LLY (7)
Institutional Metric AKRO LLY Criterion Row Edge
Market Capitalization
Scale
$4.5B $1.20T Larger Scale LLY
Trailing P/E Ratio
Valuation
N/M 44.9x Lower Multiple LLY
Forward P/E Ratio
Valuation
N/M 26.5x Lower Multiple LLY
Revenue Growth (YoY)
Growth
+0.0% +38.6% Higher Growth LLY
Operating Margin (TTM)
Profitability
0.0% 51.2% Higher Margin LLY
Net Profit Margin
Profitability
0.0% 31.9% Higher Margin LLY
Return on Equity (ROE)
Capital Efficiency
-34.5% 86.0% Higher ROE LLY
52-Week Range Position
Momentum
90% ($21–$58) 80% ($851–$1,475) Stronger Trend AKRO
Beta / 30D Volatility
Risk Regime
0.90β · 2% Vol 0.32β · 36% Vol Lower Realized Risk AKRO
Unified Institutional Score
Composite Signal
60.0 / 100 (BUY) 41.4 / 100 (SELL) Higher Composite AKRO
Trailing 12M Revenue (USD)
Operating Scale
N/A $86.5B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 83.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 1.28x PEG · 14.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($11.95 Book/Sh · -34.5% ROE) $11.7B ($44.6B Net Debt (1.23x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AKRO +5.53 pp
AKRO: +0.57% · LLY: -4.96%
3M Horizon AKRO +5.53 pp
AKRO: +0.57% · LLY: -4.96%
6M Horizon AKRO +5.53 pp
AKRO: +0.57% · LLY: -4.96%
1Y Horizon AKRO +5.53 pp
AKRO: +0.57% · LLY: -4.96%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AKRO vs LLY. Trailing 12-month operating profitability (AKRO 0.0% vs LLY 51.2%) and valuation multiples (AKRO N/M vs LLY 26.5x Forward P/E) are benchmarked directly in Pillar 4 below.

AKRO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-34.5% · N/M
LLY ADR TTM Benchmark FX-Normalized USD
TTM Revenue$86.5B
Gross Margin83.6%
Op. Margin51.2%
ROE / Fwd P/E86.0% · 26.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AKRO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 7.3%
IV Percentile 30th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AKRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LLY CONSOLIDATION
97d in phase · OBV DISTRIBUTION
Current IV 34.2%
IV Percentile 23rd %ile
Put/Call OI Skew 0.95x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact LLY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $1,431.67 · IV 32.8%

LLY Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($143,167)

Compare $143,167 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 32.8% ATM IV.

5-DAY BULLISH SWING Liq A

Dec 18 $1,420 / $1,500 Bull Call Spread

Buy 1x $1,420C · Sell 1x $1,500C · 31d

Net Entry $3,575 Debit
T+5d @ +5% Move +$1,618 (+45%)
Max Risk / Buffer $3,575 Capped
5d Edge & Liquidity 0.9x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $1,340 / $1,220 Bull Put Spread

Sell 1x $1,340P · Buy 1x $1,220P · 31d

Net Entry $1,725 Credit
Max Credit / Yield +$1,725 (+16.8% RoM)
Max Risk / Buffer -7.6% Cushion ($10,275 Mgn)
5d Edge & Liquidity 76% PoP · Liq A
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq B

Dec 18 $1,340P / $1,460-$1,540C Seagull

Sell 1x $1,340P · Buy 1x $1,460/$1,540C · 31d

Net Entry $210 Debit
T+5d @ +5% Move +$3,040 (+13.9% RoM)
Max Risk / Buffer -6.4% Put Cushion ($21,901 Mgn)
5d Edge & Liquidity 0.7x R:R · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AKRO Moat Profile Cyclical / Execution-Driven Positioning
Pharmaceutical Preparations Operator
Competes within the Pharmaceutical Preparations value chain with $4.5B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
LLY Moat Profile High-Margin Pricing Power Moat
Incretin Metabolic, Obesity & Cardiometabolic Biopharma Leader
Anchors global GLP-1/GIP metabolic therapy demand backed by multi-billion-dollar sterile fill-finish and active ingredient manufacturing scale.
OpEx & R&D Reinvestment 32.4% of Rev ($28.0B)
90D Engineering Disclosures 0 Published

Investor FAQ AKRO vs LLY Key Questions & Quantitative Answers

As of Nov 20, 2026, Eli Lilly & Co. (LLY) is the stronger overall head-to-head candidate over Akero Therapeutics, Inc. (AKRO) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AKRO carries a Unified Composite Score of 60.0/100 (BUY) at $54.65 (N/M Forward P/E, 0.0% operating margin), whereas LLY carries 41.4/100 (SELL) at $1,347.11 (26.5x Forward P/E, 51.2% operating margin). Composite vs. Pillar Nuance: While AKRO currently prints a higher short-term Unified Composite Score (60.0/100 BUY vs. LLY 41.4/100 SELL), LLY captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (51.2% vs. 0.0% operating margin) and revenue trajectory (+38.6% vs. +0.0% YoY).

LLY leads the Growth & Scale pillar: AKRO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with LLY at +38.6% YoY revenue growth and +16.3% YoY earnings growth on $86.5B TTM revenue (83.6% gross margin, 51.2% operating margin). On trailing 12-month operating scale, AKRO generates N/A in USD-normalized revenue versus $86.5B for LLY. In operating R&D and SG&A reinvestment, AKRO deploys N/A (0 90-day corporate R&D disclosures) versus 32.4% of Rev ($28.0B) (0 disclosures) for LLY.

LLY screens cheaper on headline valuation multiples. AKRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas LLY trades at 26.5x Forward P/E, 44.9x Trailing P/E, 1.28x PEG, and 14.4x EV/Revenue (13.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AKRO (-34.5% ROE) versus LLY (86.0% ROE) capital efficiency.

In options market volatility and institutional positioning, AKRO carries 7.3% implied volatility (30th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.90β · 2% Vol realized risk). By comparison, LLY carries 34.2% implied volatility (23rd %ile, Compressed (<25th %ile)), a 0.95x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.32β · 36% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.